0001178913-25-002710.txt : 20250811 0001178913-25-002710.hdr.sgml : 20250811 20250811060209 ACCESSION NUMBER: 0001178913-25-002710 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250811 DATE AS OF CHANGE: 20250811 EFFECTIVENESS DATE: 20250811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Silexion Therapeutics Corp CENTRAL INDEX KEY: 0002022416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-554233 FILM NUMBER: 251199975 BUSINESS ADDRESS: STREET 1: 12 ABBA HILLEL ROAD CITY: RAMAT GAN STATE: L3 ZIP: 5250606 BUSINESS PHONE: 972-8-6286005 MAIL ADDRESS: STREET 1: 12 ABBA HILLEL ROAD CITY: RAMAT GAN STATE: L3 ZIP: 5250606 FORMER COMPANY: FORMER CONFORMED NAME: Biomotion Sciences DATE OF NAME CHANGE: 20240506 D 1 primary_doc.xml X0708 D LIVE 0002022416 Silexion Therapeutics Corp 12 ABBA HILLEL ROAD RAMAT GAN L3 ISRAEL 5250606 +972-3-756-4999 CAYMAN ISLANDS None Biomotion Sciences Corporation true 2024 Ilan Hadar c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Executive Officer Director Mirit Horenshtein-Hadar c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Executive Officer Ruth Alon c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Director Ilan Levin c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Director Avner Lushi c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Director Shlomo Noy c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Director Amnon Peled c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Director Dror Abramov c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Director Mitchell Shirvan c/o Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan L3 ISRAEL 5250606 Executive Officer Biotechnology No Revenues 06b false 2025-08-01 false true true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor NEW YORK NY NEW YORK 10022 CT CONNECTICUT FL FLORIDA IL ILLINOIS KY KENTUCKY NY NEW YORK false 3597662 3597662 0 Form D covers new warrants issued 8/1/2025: investor warrants (304,212 at $11.32/share) and agent warrants (10,647 at $14.4625/share). Excludes exercise of warrants issued Jan 2025. Total offering amount equals exercise price of new warrants. false 11 140789 909500 7% cash fee + 1% mgmt. fee to H.C. Wainwright on warrant exercise proceeds. Finder's fees: $25,000 expense allowance, $50,000 legal/out-of-pocket expenses, & $15,950 clearing fees. HCW agent warrants instead included in Item 13. 0 Silexion Therapeutics Corp expects to use any proceeds from the future exercise of the new warrants for general corporate purposes. No proceeds are expected to be paid to executive officers, directors, or promoters. false Silexion Therapeutics Corp /s/ Ilan Hadar Ilan Hadar Chief Executive Officer 2025-08-11